Volume 18, Issue 6, Pages e1 (November 2017)

Slides:

Advertisements

Similar presentations

Fuhrman Grade and Neutrophil-To-Lymphocyte Ratio Influence on Survival in Patients With Metastatic Renal Cell Carcinoma Treated With First-Line Tyrosine.

Advertisements

MET Gene Copy Number in Non-small Cell Lung Cancer: Molecular Analysis in a Targeted Tyrosine Kinase Inhibitor Naïve Cohort Michèle Beau-Faller, MD,

Expression Levels of KMT2C and SLC20A1 Identified by Information-theoretical Analysis Are Powerful Prognostic Biomarkers in Estrogen Receptor-positive.

The clinical features and management of women with ductal carcinoma in situ with microinvasion: A retrospective Cohort study Ying Li, Sheng Zhang, Xi.

Volume 105, Issue 3, Pages (March 1994)

Volume 18, Issue 1, Pages e71-e79 (January 2017)

Erlotinib or Docetaxel for Second-Line Treatment of Non-small Cell Lung Cancer: A Real-World Cost-Effectiveness Analysis Ian Cromwell, MSc, Kimberly.

Prognostic and Predictive Markers of Benefit from Adjuvant Chemotherapy in Early- Stage Non-small Cell Lung Cancer Ana Belén Custodio, MD, José Luis González-Larriba,

Phase II Study of Gefitinib, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI), and Celecoxib, a Cyclooxygenase-2 (COX-2) Inhibitor,

Which is the Better Prognostic Factor for Resected Non-small Cell Lung Cancer: The Number of Metastatic Lymph Nodes or the Currently Used Nodal Stage.

Epidermal Growth Factor Receptor-Related Tumor Markers and Clinical Outcomes with Erlotinib in Non-small Cell Lung Cancer: An Analysis of Patients from.

BRAF Mutations in Metanephric Adenoma of the Kidney

Prognostic Significance of the Number of Lymph Nodes Removed at Lobectomy in Stage IA Non-small Cell Lung Cancer Sai-Hong Ignatius Ou, MD, PhD, Jason.

Maintenance Sunitinib following Initial Platinum-Based Combination Chemotherapy in Advanced-Stage IIIB/IV Non–Small Cell Lung Cancer: A Randomized, Double-Blind,

Increased MAPK1/3 Phosphorylation in Luminal Breast Cancer Related with PIK3CA Hotspot Mutations and Prognosis Diana Ramirez-Ardila, A. Mieke Timmermans,

Surgical quality of wedge resection affects overall survival in patients with early stage non–small cell lung cancer Gaurav S. Ajmani, MHS, Chi-Hsiung.

Prognostic Significance of TAZ Expression in Resected Non-Small Cell Lung Cancer Mian Xie, MD, PhD, Li Zhang, MD, Chao-Sheng He, MD, Jin-Hui Hou, MD,

Prognostic Significance of C-Reactive Protein and Smoking in Patients with Advanced Non-small Cell Lung Cancer Treated with First-Line Palliative Chemotherapy

Treatment With JAK Inhibitors in Myelofibrosis Patients Nullifies the Prognostic Impact of Unfavorable Cytogenetics Vincent T. Ma, Philip S. Boonstra,

APLCC ORAL ABSTRACT SESSIONS - MONDAY, NOVEMBER 26

EGFR Molecular Profiling in Advanced NSCLC: A Prospective Phase II Study in Molecularly/Clinically Selected Patients Pretreated with Chemotherapy Michele.

Susan C. Scott, MD, Nathan A. Pennell, MD, PhD

Yih-Leong Chang, MD, Chen-Tu Wu, MD, Yung-Chie Lee, MD, PhD

Survival of Patients with Cutaneous Squamous Cell Carcinoma: Results of a Prospective Cohort Study Thomas K. Eigentler, Ulrike Leiter, Hans-Martin Häfner,

Osteopontin Combined With CD44v6, a Novel Prognostic Biomarker in Non-Small Cell Lung Cancer Undergoing Curative Resection Bing-sheng Sun, MD, PhD, Yue.

XL888 Limits Vemurafenib-Induced Proliferative Skin Events by Suppressing Paradoxical MAPK Activation Manali Phadke, Geoffrey T. Gibney, Carolyn J. Rich,

Interpretation of Anti-ALK Immunohistochemistry Results

Prognostic Impact of Newly Proposed M Descriptors in TNM Classification of Non–Small Cell Lung Cancer Junghoon Shin, MD, Bhumsuk Keam, MD, PhD, Miso.

Lymph Node Evaluation Achieved by Open Lobectomy Compared With Thoracoscopic Lobectomy for N0 Lung Cancer Robert E. Merritt, MD, Chuong D. Hoang, MD,

Osteopontin-Expressing Macrophages in Non-Small Cell Lung Cancer Predict Survival Yue Li, MD, Bing-sheng Sun, MD, PhD, Baoxiang Pei, MD, Chen-guang Li,

Which is the Better Prognostic Factor for Resected Non-small Cell Lung Cancer: The Number of Metastatic Lymph Nodes or the Currently Used Nodal Stage.

Boundary between N1 and N2 Lymph Node Descriptors in the Subcarinal Zone in Lower Lobe Lung Cancer: A Brief Report Mitsuhiro Isaka, MD, Haruhiko Kondo,

Association of Phosphorylated Epidermal Growth Factor Receptor with Survival in Patients with Locally Advanced Non-small Cell Lung Cancer Treated with.

Mutational Analysis of BRAF Inhibitor–Associated Squamoproliferative Lesions Britt Clynick, Tania Tabone, Kathryn Fuller, Wendy Erber, Katie Meehan, Michael.

Predictors of Death, Local Recurrence, and Distant Metastasis in Completely Resected Pathological Stage-I Non–Small-Cell Lung Cancer Jung-Jyh Hung, MD,

Comprehensive Computational Pathological Image Analysis Predicts Lung Cancer Prognosis Xin Luo, MD, Xiao Zang, BS, Lin Yang, MD, Junzhou Huang, PhD,

Prognostic Factors in Patients with Pathologic T1-2N1M0 Disease in Non-small Cell Carcinoma of the Lung Katsunari Matsuoka, MD, Shinichi Sumitomo, MD,

Interstitial tumor-associated macrophages combined with tumor-derived colony- stimulating factor-1 and interleukin-6, a novel prognostic biomarker in non–small.

Mediastinal Lymph Node Examination and Survival in Resected Early-Stage Non– Small-Cell Lung Cancer in the Surveillance, Epidemiology, and End Results.

Impact of Positive Nodal Metastases in Patients with Thymic Carcinoma and Thymic Neuroendocrine Tumors Benny Weksler, MD, Anthony Holden, MD, Jennifer.

Tumor-Infiltrating Foxp3+ Regulatory T Cells are Correlated with Cyclooxygenase-2 Expression and are Associated with Recurrence in Resected Non-small.

PD-L1 as a Companion Biomarker for Immune Checkpoint Inhibitors in NSCLC: Should RNA ISH (RISH) Be Considered? Steven G. Gray, PhD Journal of Thoracic.

Extratumoral Vascular Invasion Is a Significant Prognostic Indicator and a Predicting Factor of Distant Metastasis in Non-small Cell Lung Cancer Yoshihisa.

A Comprehensive Analysis of p16 Expression, Gene Status, and Promoter Hypermethylation In Surgically Resected Non-small Cell Lung Carcinomas William.

Icotinib in Patients with Pretreated Advanced Esophageal Squamous Cell Carcinoma with EGFR Overexpression or EGFR Gene Amplification: A Single-Arm, Multicenter.

Prognostic and Predictive Markers of Benefit from Adjuvant Chemotherapy in Early- Stage Non-small Cell Lung Cancer Ana Belén Custodio, MD, José Luis González-Larriba,

Loss of p16INK4A Expression and Homozygous CDKN2A Deletion Are Associated with Worse Outcome and Younger Age in Thymic Carcinomas Scott W. Aesif, MD,

Prognostic Impact of Node Involvement Pattern in Pulmonary pN1 Squamous Cell Carcinoma Patients Masayuki Nakao, MD, Junji Yoshida, MD, PhD, Genichiro.

Vamsidhar Velcheti, MD Journal of Thoracic Oncology

Phase II Study of the Histone Deacetylase Inhibitor Romidepsin in Relapsed Small Cell Lung Cancer (Cancer and Leukemia Group B 30304) Gregory A. Otterson,

ALK Translocation in Non-small Cell Lung Cancer with Adenocarcinoma and Squamous Cell Carcinoma Markers Samuel J. Klempner, MD, David W. Cohen, MD, Daniel.

Impact of Non–Small-Cell Lung Cancer-Not Otherwise Specified Immunophenotyping on Treatment Outcome Luisella Righi, MD, PhD, Tiziana Vavalà, MD, Ida.

Tumor-Stroma Ratio Is an Independent Predictor for Survival in Esophageal Squamous Cell Carcinoma kai Wang, MD, Wei Ma, MD, Jianbo Wang, MD, Liang Yu,

Newly Discovered Olfactory Receptors in Epidermal Keratinocytes Are Associated with Proliferation, Migration, and Re-Epithelialization of Keratinocytes

Nabil P. Rizk, MD, Venkatraman E. Seshan, PhD, Manjit S

Gemcitabine in Brief versus Prolonged Low-Dose Infusion, both Combined with Cisplatin, for Advanced Non-small Cell Lung Cancer: A Randomized Phase II.

Clinical Relevance of Our Multimodality Prognostic Score

It’s All in the “Swerve of the Curve”

Michael Hsie, MD, Stefania Morbidini-Gaffney, MD, Leslie J

Primary Small Cell Carcinoma of the Esophagus

Development of a patient-centered aggregate score to predict survival after lung resection for non–small cell lung cancer Alessandro Brunelli, MD, Michele.

Impact of Tumor Size on Local Control and Pneumonitis After Stereotactic Body Radiation Therapy for Lung Tumors Sean M. Parker, BS, R. Alfredo Siochi,

Thymidylate Synthase Protein Expression by IHC and Gene Copy Number by SISH Correlate and Show Great Variability in Non–Small Cell Lung Cancer Murry.

Volume 82, Issue 9, Pages (November 2012)

APLCC POSTER SESSION 2 - WEDNESDAY, NOVEMBER 28

Impact of Immunotherapy after Resection of Pancreatic Cancer

A Phase I Evaluation of Oral CI-1033 in Combination with Paclitaxel and Carboplatin as First-Line Chemotherapy in Patients with Advanced Non-small Cell.

Surveillance Epidemiology and End Results Evaluation of the Role of Surgery for Stage I Small Cell Lung Cancer James B. Yu, MD, Roy H. Decker, MD, PhD,

A Dramatic Response to Crizotinib in a Non–Small-Cell Lung Cancer Patient with IHC- Positive and FISH-Negative ALK Jong-Mu Sun, MD, PhD, Yoon-La Choi,

Kristin A. Higgins, MD, Junzo P. Chino, MD, Neal Ready, MD, Mark W

Presentation transcript:

Volume 18, Issue 6, Pages 667-674.e1 (November 2017) Prognostic Role of the FGFR4-388Arg Variant in Lung Squamous-Cell Carcinoma Patients With Lymph Node Involvement Álvaro Quintanal-Villalonga, Andrés Carranza-Carranza, Ricardo Meléndez, Irene Ferrer, Sonia Molina-Pinelo, Luis Paz-Ares Clinical Lung Cancer Volume 18, Issue 6, Pages 667-674.e1 (November 2017) DOI: 10.1016/j.cllc.2017.05.008 Copyright © 2017 The Author(s) Terms and Conditions

Figure 1 FGFR4-388Arg Variant Correlates With Higher MAPK Activation. Representative Images of IHC Staining for pAKT and pERK in FGFR4-388Gly (Gly) and -388Arg (Arg) Patients Abbreviations: IHC = immunohistochemistry; MAPK = mitogen-activated protein kinase; pAKT = phosphorylated protein kinase B; pERK = phosphorylated extracellular signal–regulated kinase. Clinical Lung Cancer 2017 18, 667-674.e1DOI: (10.1016/j.cllc.2017.05.008) Copyright © 2017 The Author(s) Terms and Conditions

Figure 2 Kaplan-Meier Survival Plots for Overall and Progression-Free Survival. FGFR4-388Arg Variant Correlates With Poorer Overall and Progression-free Survival in SCC Patients With Lymph Node Involvement. Kaplan-Meier Survival Plots Are Shown for Overall and Progression-free Survival in Entire SCC Cohort and in SCC Patients With Lymph Node Involvement Abbreviations: Arg = FGFR4-388Arg; Gly = FGFR4-388Gly; SCC = squamous-cell carcinoma. Clinical Lung Cancer 2017 18, 667-674.e1DOI: (10.1016/j.cllc.2017.05.008) Copyright © 2017 The Author(s) Terms and Conditions